Search Results
Search for other papers by Kusum Lata in
Google Scholar
PubMed
Search for other papers by Pinaki Dutta in
Google Scholar
PubMed
Search for other papers by Subbiah Sridhar in
Google Scholar
PubMed
Search for other papers by Minakshi Rohilla in
Google Scholar
PubMed
Search for other papers by Anand Srinivasan in
Google Scholar
PubMed
Search for other papers by G R V Prashad in
Google Scholar
PubMed
Search for other papers by Viral N Shah in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
Objectives
Thyroid antibody positivity during pregnancy has been associated with adverse outcomes including miscarriage and preterm delivery. The aim of the study is to evaluate the obstetric outcome in pregnant women with recurrent miscarriage and their response to levothyroxine (l-T4) therapy.
Study design and methods
All pregnant and non-pregnant women between 21 and 35 years of age with a history of two or more consecutive miscarriages were included in the study. A third group comprising 100 pregnant women without a history of miscarriage were taken as healthy controls. Thyroid autoimmunity, prevalence of subclinical hypothyroidism and maternal and foetal complications were analysed in all the groups with appropriate statistical methods.
Results
The mean age of the patients included in the study was 27.0±3.1 years. Of 100 pregnant patients with previous recurrent miscarriage, thyroid autoimmunity (thyroid peroxidase antibody (TPOAb+) >34 U/ml) was found in 31% of the cases. The incidence of subclinical hypothyroidism was higher in TPOAb+ group than in TPOAb− group (52 vs 16%; P=0.0002). There was no difference in the prevalence of miscarriage or obstetric outcomes between recurrent miscarriage and healthy pregnant women group irrespective of TPO status.
Conclusions
The prevalence of thyroid autoimmunity was higher in pregnant women with a history of recurrent abortion compared with healthy pregnant control population. Following l-T4 treatment, there was no difference in prevalence of miscarriage between hypothyroid and euthyroid individuals in TPOAb+ women.
Search for other papers by Liza Das in
Google Scholar
PubMed
Search for other papers by Kim Vaiphei in
Google Scholar
PubMed
Search for other papers by Ashutosh Rai in
Google Scholar
PubMed
Search for other papers by Chirag Kamal Ahuja in
Google Scholar
PubMed
Search for other papers by Paramjeet Singh in
Google Scholar
PubMed
Search for other papers by Ishani Mohapatra in
Google Scholar
PubMed
Search for other papers by Rajesh Chhabra in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
Search for other papers by Bishan Dass Radotra in
Google Scholar
PubMed
Green Templeton College, University of Oxford, Oxford, UK
Search for other papers by Ashley B Grossman in
Google Scholar
PubMed
Search for other papers by Márta Korbonits in
Google Scholar
PubMed
Search for other papers by Pinaki Dutta in
Google Scholar
PubMed
Objective
Posterior pituitary tumours (PPTs) are rare neoplasms with the four recognised subtypes unified by thyroid transcription factor -1 (TTF-1) expression, according to the 2017 WHO classification. Though traditionally defined as low-grade neoplasms, a substantial proportion of them show recurrence/persistence following surgery.
Methods
We selected patients with PPTs in our cohort of 1760 patients operated for pituitary tumours over the past 10 years (2010–2019). The clinical, radiological, hormonal, histopathological profiles and long-term outcomes of the three cases identified (two pituicytomas and one spindle cell oncocytoma, SCO) were analysed. Following a literature review, data of all published cases with documented TTF-1 positive pituicytomas and SCOs were analysed to determine the predictors of recurrence/persistence in these tumours.
Results
Patients presented with compressive features or hypogonadism. Two had sellar-suprasellar masses. One had a purely suprasellar mass with a pre-operative radiological suspicion of pituicytoma. Two were operated by transsphenoidal surgery and one transcranially guided by neuronavigation. Histopathology confirmed spindle cells in a storiform arrangement and low Ki67 index. Immunohistochemistry showed positive TTF-1, S-100 expression and variable positivity for EMA, vimentin and GFAP. Re-evaluation showed recurrence/persistence in two patients. A literature review of recurrent/persistent pituicytoma (n = 17) and SCO (n = 9) cases revealed clinical clues (headache for pituicytomas, male gender for SCO), baseline tumour size (≥20.5 mm with sensitivity exceeding 80%) and longer follow-up duration as determinants of recurrence/persistence.
Conclusion
PPTs are rare sellar masses with quintessential TTF-1 positivity. Recurrent/persistent disease following surgery is determined by greater tumour size at baseline and duration of follow-up. This warrants intensive and long-term surveillance in these patients.
Search for other papers by Kush Dev Singh Jarial in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
Search for other papers by Vivek Gupta in
Google Scholar
PubMed
Search for other papers by Paramjeet Singh in
Google Scholar
PubMed
Search for other papers by Kanchan K Mukherjee in
Google Scholar
PubMed
Search for other papers by Akhilesh Sharma in
Google Scholar
PubMed
Search for other papers by Rakesh K Vashishtha in
Google Scholar
PubMed
Search for other papers by Suja P Sukumar in
Google Scholar
PubMed
Search for other papers by Naresh Sachdeva in
Google Scholar
PubMed
Search for other papers by Rama Walia in
Google Scholar
PubMed
Context
Bilateral inferior petrosal sinus sampling (BIPSS) using hCRH is currently considered the ‘gold standard’ test for the differential diagnosis of ACTH-dependent Cushing’s syndrome (CS). Vasopressin is more potent than CRH to stimulate ACTH secretion as shown in animal studies; however, no comparative data of its use are available during BIPSS.
Objective
To study the diagnostic accuracy and comparison of hCRH and lysine vasopressin (LVP) stimulation during BIPSS.
Patients and methods
29 patients (27-Cushing’s disease, 2-ectopic CS; confirmed on histopathology) underwent BIPSS and were included for the study. Patients were randomized to receive hCRH, 5 U LVP or 10 U LVP during BIPSS for ACTH stimulation. BIPSS and contrast-enhanced magnetic resonance imaging (CEMRI) were compared with intra-operative findings of trans-sphenoidal surgery (TSS) for localization and lateralization of the ACTH source.
Results
BIPSS correctly localized the source of ACTH excess in 29/29 of the patients with accuracy of 26/26 patients, using any of the agent, whereas sensitivity and PPV for lateralization with hCRH, 5 U LVP and 10 U LVP was seen in 10/10, 6/10; 10/10,8/10 and 7/7,6/7 patients respectively. Concordance of BIPSS with TSS was seen in 20/27, CEMRI with BIPSS in 16/24 and CEMRI with TSS in 18/24 of patients for lateralizing the adenoma. Most of the side effects were transient and were comparable in all the three groups.
Conclusion
BIPSS using either hCRH or LVP (5 U or 10 U) confirmed the source of ACTH excess in all the patients, while 10 U LVP correctly lateralized the pituitary adenoma in three fourth of the patients.
Search for other papers by Kranti Khadilkar in
Google Scholar
PubMed
Search for other papers by Vijaya Sarathi in
Google Scholar
PubMed
Search for other papers by Rajeev Kasaliwal in
Google Scholar
PubMed
Search for other papers by Reshma Pandit in
Google Scholar
PubMed
Search for other papers by Manjunath Goroshi in
Google Scholar
PubMed
Search for other papers by Gaurav Malhotra in
Google Scholar
PubMed
Search for other papers by Abhay Dalvi in
Google Scholar
PubMed
Search for other papers by Ganesh Bakshi in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
Search for other papers by Rajesh Rajput in
Google Scholar
PubMed
Search for other papers by Vyankatesh Shivane in
Google Scholar
PubMed
Search for other papers by Anurag Lila in
Google Scholar
PubMed
Search for other papers by Tushar Bandgar in
Google Scholar
PubMed
Search for other papers by Nalini S Shah in
Google Scholar
PubMed
Background and aims
Malignant transformation of pheochromocytomas/paragangliomas (PCC/PGL) is a rare occurrence, and predictive factors for the same are not well understood. This study aims to identify the predictors of malignancy in patients with PCC/PGL.
Materials and methods
We performed a retrospective analysis of 142 patients with either PCC or PGL registered at our institute between 2000 and 2015. Records were evaluated for clinical parameters like age, gender, familial/syndromic presentation, symptomatic presentation, biochemistry, size, number and location of tumours and presence of metastases and mode of its diagnosis.
Results
Twenty patients were found to have metastases; 13 had metastases at diagnosis and seven during follow-up. Metastases were detected by radiology (CT-neck to pelvis) in 11/20 patients (5/13 synchronous and 6/7 metachronous), 131I-metaiodobenzylguanidine in five (2/12 synchronous and 3/6 metachronous) patients and 18F-flurodeoxyglucose PET/CT in 15 (12/12 synchronous and 3/3 metachronous) patients. Malignant tumours were significantly larger than benign tumours (8.3 ± 4.1 cm, range: 3–22 cm vs 5.7 ± 2.3 cm, range: 2–14 cm, P = 0.0001) and less frequently metanephrine secreting. On linear regression analysis, tumour size and lack of metanephrine secretion were the independent predictors of malignancy.
Conclusions
Patients with primary tumour size >5.7 cm and lack of metanephrine secretory status should be evaluated for possible malignancy not only at diagnosis but also in the postoperative period. As compared to CT and 131I-MIBG scan, 18F-flurodeoxyglucose PET/CT analyses are better (sensitivity: 100%) for the diagnosis of metastases in our study.
Search for other papers by Pinaki Dutta in
Google Scholar
PubMed
Search for other papers by Bhuvanesh Mahendran in
Google Scholar
PubMed
Search for other papers by K Shrinivas Reddy in
Google Scholar
PubMed
Search for other papers by Jasmina Ahluwalia in
Google Scholar
PubMed
Search for other papers by Kim Vaiphei in
Google Scholar
PubMed
Search for other papers by Rakesh K Kochhar in
Google Scholar
PubMed
Search for other papers by Prakamya Gupta in
Google Scholar
PubMed
Search for other papers by Anand Srinivasan in
Google Scholar
PubMed
Search for other papers by Mahesh Prakash in
Google Scholar
PubMed
Search for other papers by Kanchan Kumar Mukherjee in
Google Scholar
PubMed
Search for other papers by Viral N Shah in
Google Scholar
PubMed
Search for other papers by Girish Parthan in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
The effectiveness and short-term safety of recombinant human GH (r-hGH) in acromegaly patients with GH deficiency (GHD) after treatment are not well established. The study includes ten subjects with acromegaly who had GHD treated with r-hGH for 6 months. Control groups consisted of ten age-, gender-, and BMI-matched healthy subjects and ten active acromegaly patients who were treatment naïve. Body composition, quality of life (QoL), muscle strength, lipid profile, and cardiovascular risk factors were assessed in all subjects at baseline, and the same parameters were reassessed after 6 months of therapy with r-hGH in acromegaly with GHD. Repeat magnetic resonance imaging of the sella was performed in treated subjects. Optical colonoscopy was done and biopsies were taken from multiple sites for proliferation indices (Ki67). The median duration of GHD was 17.8 months and dose of r-hGH administered was 5.7±1.5 μg/kg per day. There was improvement in bone mineral content (P=0.01), bone mineral density (P=0.04), muscle strength (P<0.001), total cholesterol (P=0.003), high-density cholesterol (P<0.001), and QoL – score (P=0.005), and reduction in low-density cholesterol (P=0.003) and triglyceride (P=0.004) after treatment. There was no change in lean body mass, total body fat, hsCRP, lipoprotein (a), and fibrinogen levels. There was a modest increase in plasminogen activator inhibitor 1 (P=0.002), but it was lower compared with healthy controls and treatment naïve acromegalics (P=0.007). Six month-r-hGH therapy improves body composition, atherogenic lipid profile, QoL, and muscle strength in GHD patients who had acromegaly. Long-term prospective studies are needed to evaluate the effect of r-hGH therapy in these patients.
Search for other papers by Rimesh Pal in
Google Scholar
PubMed
Search for other papers by Sanjay Kumar Bhadada in
Google Scholar
PubMed
Search for other papers by Awesh Singhare in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
Search for other papers by Sadishkumar Kamalanathan in
Google Scholar
PubMed
Search for other papers by Manoj Chadha in
Google Scholar
PubMed
Search for other papers by Phulrenu Chauhan in
Google Scholar
PubMed
Search for other papers by Ashwani Sood in
Google Scholar
PubMed
Search for other papers by Vandana Dhiman in
Google Scholar
PubMed
Search for other papers by Dinesh Chandra Sharma in
Google Scholar
PubMed
Search for other papers by Uma Nahar Saikia in
Google Scholar
PubMed
Search for other papers by Debajyoti Chatterjee in
Google Scholar
PubMed
Search for other papers by Vikas Agashe in
Google Scholar
PubMed
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by recalcitrant hypophosphatemia. Reports from the Indian subcontinent are scarce, with most being single center experiences involving few patients. Herein, we conducted a retrospective analysis of 30 patients of TIO diagnosed at three tertiary care hospitals in India. Patients with persistent hypophosphatemia (despite correction of hypovitaminosis D), normocalcemia, elevated alkaline phosphatase, low TmP/GFR and elevated or ‘inappropriately normal’ FGF23 levels were labeled as having TIO. They were sequentially subjected to functional followed by anatomical imaging. Patients with a well-localized tumor underwent excision; others were put on phosphorous and calcitriol supplementation. The mean age at presentation was 39.6 years with female:male ratio of 3:2. Bone pain (83.3%) and proximal myopathy (70%) were the chief complaints; 40% of cases had fractures. The mean delay in diagnosis was 3.8 years. Tumors were clinically detectable in four patients (13.3%). The mean serum phosphate was 0.50 mmol/L with a median serum FGF23 level of 518 RU/mL. Somatostatin receptor-based scintigraphy was found to be superior to FDG-PET in tumor localization. Lower extremities were the most common site of the tumor (72%). Tumor size was positively correlated with serum FGF23 levels. Twenty-two patients underwent tumor resection and 16 of them had phosphaturic mesenchymal tumors. Surgical excision led to cure in 72.7% of patients whereas disease persistence and disease recurrence were seen in 18.2% and 9.1% of cases, respectively. At the last follow-up, serum phosphate in the surgically treated group was significantly higher than in the medically managed group.
Search for other papers by Ghazala Zaidi in
Google Scholar
PubMed
Search for other papers by Vijayalakshmi Bhatia in
Google Scholar
PubMed
Search for other papers by Saroj K Sahoo in
Google Scholar
PubMed
Search for other papers by Aditya Narayan Sarangi in
Google Scholar
PubMed
Search for other papers by Niharika Bharti in
Google Scholar
PubMed
Search for other papers by Li Zhang in
Google Scholar
PubMed
Search for other papers by Liping Yu in
Google Scholar
PubMed
Search for other papers by Daniel Eriksson in
Google Scholar
PubMed
Search for other papers by Sophie Bensing in
Google Scholar
PubMed
Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Sweden
Search for other papers by Olle Kämpe in
Google Scholar
PubMed
Search for other papers by Nisha Bharani in
Google Scholar
PubMed
Search for other papers by Surendra Kumar Yachha in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
Search for other papers by Alok Sachan in
Google Scholar
PubMed
Search for other papers by Vandana Jain in
Google Scholar
PubMed
Search for other papers by Nalini Shah in
Google Scholar
PubMed
Search for other papers by Rakesh Aggarwal in
Google Scholar
PubMed
Search for other papers by Amita Aggarwal in
Google Scholar
PubMed
Search for other papers by Muthuswamy Srinivasan in
Google Scholar
PubMed
Search for other papers by Sarita Agarwal in
Google Scholar
PubMed
Search for other papers by Eesh Bhatia in
Google Scholar
PubMed
Objective
Autoimmune polyendocrine syndrome type 1 (APS1) is a rare autosomal recessive disorder characterized by progressive organ-specific autoimmunity. There is scant information on APS1 in ethnic groups other than European Caucasians. We studied clinical aspects and autoimmune regulator (AIRE) gene mutations in a cohort of Indian APS1 patients.
Design
Twenty-three patients (19 families) from six referral centres in India, diagnosed between 1996 and 2016, were followed for [median (range)] 4 (0.2–19) years.
Methods
Clinical features, mortality, organ-specific autoantibodies and AIRE gene mutations were studied.
Results
Patients varied widely in their age of presentation [3.5 (0.1–17) years] and number of clinical manifestations [5 (2–11)]. Despite genetic heterogeneity, the frequencies of the major APS1 components (mucocutaneous candidiasis: 96%; hypoparathyroidism: 91%; primary adrenal insufficiency: 55%) were similar to reports in European series. In contrast, primary hypothyroidism (23%) occurred more frequently and at an early age, while kerato-conjunctivitis, urticarial rash and autoimmune hepatitis were uncommon (9% each). Six (26%) patients died at a young age [5.8 (3–23) years] due to septicaemia, hepatic failure and adrenal/hypocalcaemic crisis from non-compliance/unexplained cause. Interferon-α and/or interleukin-22 antibodies were elevated in all 19 patients tested, including an asymptomatic infant. Eleven AIRE mutations were detected, the most common being p.C322fsX372 (haplotype frequency 37%). Four mutations were novel, while six others were previously described in European Caucasians.
Conclusions
Indian APS1 patients exhibited considerable genetic heterogeneity and had highly variable clinical features. While the frequency of major manifestations was similar to that of European Caucasians, other features showed significant differences. A high mortality at a young age was observed.